Phase 3 Multiple Sclerosis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with relapsing multiple sclerosis (MS), based on specific diagnostic guidelines from 2017.
• You have either never been treated for MS before, or you have previously taken an MS medication but stopped it before joining and have waited long enough since stopping.
• Your level of physical disability, as measured by a standard MS scale, is at or below a certain moderate level (confirm with trial site).
• Your MS symptoms have been stable for more than 30 days before starting the study drug.
• If you are a woman who could become pregnant, you must agree to use an effective form of birth control from the start of the study until 6 months after your last dose of the study drug.
• (For one part of the study only) You are currently being treated with a specific type of MS medication called an anti-CD20 therapy, have been on it for at least 6 months, and stopped it because it did not work well enough for you or caused problems.

Who may not be able to join:

• You have previously had a severe allergic or infusion reaction to an anti-CD20 type of medication.
• You have a type of MS that is primary-progressive, or a form of secondary progressive MS that is no longer active.
• You have another ongoing condition where your immune system attacks your body (such as rheumatoid arthritis, Crohn's disease, or similar conditions), or you have an immune deficiency condition.
• You have a serious ongoing or long-term infection (such as tuberculosis, a long-term urinary tract infection, or active hepatitis C) that requires long-term treatment.
• You have previously had a serious or unusual type of infection (confirm with trial site).
• You have a current or past hepatitis B infection, or an active hepatitis C infection (some exceptions may apply — confirm with trial site).
• You have ever shown signs, or there is suspicion, of a serious brain infection called PML (progressive multifocal leukoencephalopathy).
• You have received a live vaccine (such as for chickenpox or measles) within the 4 weeks before starting the study drug.
• You have needed a treatment called IVIG for low antibody levels in the 12 months before joining the study.
• You currently have or have recently had a cancer, other than certain fully treated minor skin cancers.
• You have ever been treated with any of the following medications: ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab — for any reason.

Important: Always verify eligibility with the trial site directly before applying.